Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308269 · ClinicalTrials.gov registry record · Phase 1
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
A Phase 1 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00308269: Completed Phase 1 study, sponsored by Endocyte.
NCT00308269 is a Phase 1 study that has completed, run by Endocyte. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308269, a Phase 1 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase I clinical trial evaluating the safety and tolerability of escalating doses of vintafolide (EC145) in participants with relapsed or refractory advanced tumors. The primary objective of this study is to determine the safety and maximum tolerated dose of vintafolide given by intravenous bolus or infusion. The efficacy of the treatment will also be measured.
Interventions
- DRUG Vintafolide IV Bolus
- DRUG Vintafolide IV Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00308269
The ClinicalTrials.gov registry entry for NCT00308269 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vintafolide IV Bolus is the first listed.
NCT00308269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00308269 about?
NCT00308269 is a clinical study titled "Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)". This is a Phase I clinical trial evaluating the safety and tolerability of escalating doses of vintafolide (EC145) in participants with relapsed or refractory advanced tumors. The primary objective of this study is to determine the safety and maximum tolerated dose of vintafolide given by intravenou...
What is the current status of trial NCT00308269?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00308269?
The interventions under investigation include: Vintafolide IV Bolus (DRUG), Vintafolide IV Infusion (DRUG).
Who is sponsoring clinical trial NCT00308269?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.